Frequency, Predictors, and Prognosis of Sustained Minimal Disease Activity in an Observational Psoriatic Arthritis Cohort

被引:108
作者
Coates, Laura C. [2 ]
Cook, Richard [3 ]
Lee, Ker-Ai [3 ]
Chandran, Vinod
Gladman, Dafna D. [1 ]
机构
[1] Univ Toronto, Toronto Western Hosp, Univ Hlth Network, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada
[2] Univ Leeds, Chapel Allerton Hosp, Leeds, W Yorkshire, England
[3] Univ Waterloo, Waterloo, ON N2L 3G1, Canada
基金
加拿大健康研究院;
关键词
RHEUMATOID-ARTHRITIS; CLINICAL REMISSION; RELIABILITY; PROGRESSION; DACTYLITIS; JOINTS; TRIAL; DAMAGE;
D O I
10.1002/acr.20162
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To establish the frequency and predictors of minimal disease activity in psoriatic arthritis (PsA) and to investigate the prognostic ability of minimal disease activity criteria to predict future joint damage. Methods. The study was conducted using an observational PsA cohort. Patients were classified as being in minimal disease activity if they fulfilled the criteria on consecutive visits for >12 months. Predictive factors for minimal disease activity and joint damage were investigated using regression models. Joint damage progression was based on clinically damaged joint counts. Results. Of the 344 patients, 208 (60%) achieved minimal disease activity at >= 1 visit and 116 (34%) achieved minimal disease activity for > 12 months (sustained minimal disease activity). The average duration of minimal disease activity was 28 months (range 12-48 months). Twelve patients (10%) experienced a flare of disease after 34 months in minimal disease activity. Low erythrocyte sedimentation rate (ESR) and oligoarthritis were predictors of achieving sustained minimal disease activity (P < 0.03). The mean change in damaged joint counts was 0.931 (range 0-12) in the sustained minimal disease activity group and 2.245 (range 0-17) in the controls (P < 0.001). Of the sustained minimal disease activity group, 69% showed no progression of joint damage, compared with 51% in the control group. Elevated ESR, baseline joint damage, and use of biologic therapies increased the likelihood of damage progression (P < 0.05). Conclusion. Minimal disease activity was achieved by a significant proportion of patients and was sustained in one-third of the population studied. Patients achieving sustained minimal disease activity had a significant reduction in joint damage progression. Other factors, representing disease activity and disease severity, impact on the likelihood of achieving sustained minimal disease activity and on damage progression.
引用
收藏
页码:970 / 976
页数:7
相关论文
共 19 条
[11]  
GLADMAN DD, 1990, J RHEUMATOL, V17, P809
[12]  
Healy PJ, 2007, J RHEUMATOL, V34, P1302
[13]  
Kavanaugh A, 2006, CLIN EXP RHEUMATOL, V24, pS83
[14]  
Lindqvist URC, 2008, J RHEUMATOL, V35, P668
[15]   Etanercept treatment of psoriatic arthritis - Safety, efficacy, and effect on disease progression [J].
Mease, PJ ;
Kivitz, AJ ;
Burch, FX ;
Siegel, EL ;
Cohen, SB ;
Ory, P ;
Salonen, D ;
Rubenstein, J ;
Sharp, JT ;
Tsuji, W .
ARTHRITIS AND RHEUMATISM, 2004, 50 (07) :2264-2272
[16]   Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial [J].
Mease, PJ ;
Gladman, DD ;
Ritchlin, CT ;
Ruderman, EM ;
Steinfeld, SD ;
Choy, EHS ;
Sharp, JT ;
Ory, PA ;
Perdok, RJ ;
Weinberg, MA .
ARTHRITIS AND RHEUMATISM, 2005, 52 (10) :3279-3289
[17]   Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment - Results from the induction and maintenance psoriatic arthritis clinical trial 2 [J].
van der Heijde, D. ;
Kavanaugh, A. ;
Gladman, D. D. ;
Antoni, C. ;
Krueger, G. G. ;
Guzzo, C. ;
Zhou, B. ;
Dooley, L. T. ;
de Vlam, K. ;
Geusens, P. ;
Birbara, C. ;
Halter, D. ;
Beutler, A. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (08) :2698-2707
[18]   Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease [J].
Wakefield, RJ ;
Green, MJ ;
Marzo-Ortega, H ;
Conaghan, PG ;
Gibbon, WW ;
McGonagle, D ;
Proudman, S ;
Emery, P .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (04) :382-385
[19]  
Wells GA, 2005, J RHEUMATOL, V32, P2016